Pembrolizumab with chemotherapy is approved by the USFDA for HER2-negative gastric or gastroesophageal junction adenocarcinoma
The Food and Drug Administration approved pembrolizumab (Keytruda, Merck) in combination with fluoropyrimidine- and platinum-containing chemotherapy on November 16, 2023. This approval is for the initial treatment of adults with ..
FDA revises pembrolizumab’s indication for gastric cancer
The Food and Drug Administration updated the approved use of pembrolizumab (Keytruda, Merck) in combination with trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy for treating HER2-positive gastric or gastroeso..
Bristol Myers Squibb, Residual pathologic disease
Nivolumab has been approved by the FDA for resected esophageal or gastroesophageal junction cancer
August 2021: The FDA has approved Nivolumab (Opdivo, Bristol-Myers Squibb Company) for patients with fully resected oesophagus or gastroesophageal junction (GEJ) cancer who have received neoadjuvant chemoradiotherapy and have pers..
fluoropyrimidine, gastroesophageal junction (GEJ) adenocarcinoma, KEYTRUDA, Merck & Co, Pembrolizumab, Trastuzumab
Pembrolizumab receives accelerated approval from the FDA for HER2-positive gastric cancer
August 2021: Pembrolizumab (Keytruda, Merck & Co.) in combination with trastuzumab, fluoropyrimidine-, and platinum-containing chemotherapy has been granted accelerated approval by the Food and Drug Administration for the firs..
Bristol Myers Squibb, CHECKMATE-649, fluoropyrimidine, nivolumab, Opdivo, platinum-containing chemotherapy
Nivolumab in addition to chemotherapy is approved by FDA for metastatic gastric cancer and esophageal adenocarcinoma
August 2021: For advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) in conjunction wit..
cisplatin, esophageal carcinoma, fluorouracil, GEJ, KEYNOTE-590, NCT03189719, Pembrolizumab
Pembrolizumab has been approved by the FDA for the treatment of esophageal or gastroesophageal junction cancer
August 2021: Pembrolizumab (Keytruda, Merck Sharp & Dohme Corp.) in combination with platinum and fluoropyrimidine-based chemotherapy has been approved by the Food and Drug Administration for patients with metastatic or locall..
High tumor burden, Immunotherapy, KEYTRUDA, Pembrolizumab, TMB-H
Pembrolizumab approved for use in any cancer with a high tumor mutational burden
July 2021: The US Food and Medication Administration (FDA) has expanded the indications for pembrolizumab (Keytruda), an immunotherapy drug, to encompass any cancer with a high mutational burden (TMB-H). The new authorization is f..
Easily adoptable methods to improve outcomes in treatment of gastroesophageal cancers
July 9th 2021: During the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2021, two scientists from Roswell Park Comprehensive Cancer Center were asked to share new findings on the treatment ..
FDA, Lonsurf, TAGS (NCT02500043), tipiracil tablets, Trifluridine
Lonsurf is approved by FDA for recurrent, metastatic gastric and gastroesophageal junction adenocarcinoma
Trifluridine/tipiracil tablets (LONSURF, Taiho Pharmaceutical Co., Ltd.) were approved by the Food and Drug Administration on February 22, 2019 for adult patients with metastatic gastric or gastroesophageal junction (GEJ) adenocar..
CAR T, CAR T-Cell, Cell therapy, EGFR, EGFR806, GPC3, PC-T cells, Sun Yat-sen, TGF β
CAR T-Cell therapy approvals and availability
July 2021: In June 2014, KITE Biotechnology Company, with only 19 employees, was listed on NASDAQ in the United States, and it took 130 million US dollars in one day! Just two months later, Juno Biotechnology had less than 20 em..